These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of long-term phosphodiesterase-5 inhibitor use on refractory lymphatic malformations in adult and teen patients.
    Author: Nelson KJ, Antiquera P, Nelson JS, Kelly KM, Abi-Jaoudeh N.
    Journal: J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):258-261. PubMed ID: 32305583.
    Abstract:
    Lymphatic malformations (LMs) are rare congenital anomalies. LMs are often refractory to standard treatments, including surgical resection, debulking, and sclerotherapy. Use of sildenafil, a phosphodiesterase-5 inhibitor, for treatment of pediatric LMs has been reported with demonstrated benefit to some patients. This case series reports treatment of three patients (aged 14-37 years) suffering from complicated or refractory LMs with a low-dose oral phosphodiesterase-5 inhibitor, resulting in significant clinical improvement.
    [Abstract] [Full Text] [Related] [New Search]